[Metabolic bone diseases : what's new in 2025].

In 2025, osteoporosis management in Switzerland benefited from the introduction of abaloparatide, an anabolic PTHrP analogue that effectively reduces the risk of vertebral and non-vertebral fractures, with reimbursement criteria identical to those of romosozumab. Zoledronate, administered preventively only twice at a five-year interval in recently menopausal, non-osteoporotic women, lowers 10-year fracture risk by about 40 %. Calcium and/or vitamin D supplements are now subject to reimbursement restrictions. Burosumab, an anti-FGF23 antibody, has become the treatment of choice for X-linked hypophosphatemic rickets, though access remains limited in Switzerland. Finally, artificial intelligence is emerging as a valuable tool for radiographic diagnosis and opportunistic screening of osteoporotic fractures.